Chemoprevention in Barrett's Esophagus: Current Status

Muhammad H. Zeb; Anushka Baruah; Sarah K. Kossak; Navtej S. Buttar

doi:10.1016/j.gtc.2015.02.009

Chemoprevention in Barrett's Esophagus: Current Status

Muhammad H. Zeb, Anushka Baruah, Sarah K. Kossak, Navtej S. Buttar

Gastroenterology and Hepatology

Research output: Contribution to journal › Review article › peer-review

6 Scopus citations

Abstract

Chemoprevention in Barrett's esophagus is currently applied only in research settings. Identifying pathways that can be targeted by safe, pharmaceutical or natural compounds is key to expanding the scope of chemoprevention. Defining meaningful surrogate markers of cancer progression is critical to test the efficacy of chemopreventive approaches. Combinatorial chemoprevention that targets multiple components of the same pathway or parallel pathways could reduce the risk and improve the efficacy of chemoprevention. Here we discuss the role of chemoprevention as an independent or an adjuvant management option in BE-associated esophageal adenocarcinoma.

Original language	English (US)
Pages (from-to)	391-413
Number of pages	23
Journal	Gastroenterology Clinics of North America
Volume	44
Issue number	2
DOIs	https://doi.org/10.1016/j.gtc.2015.02.009
State	Published - Jun 1 2015

Keywords

Barrett's esophagus
Chemoprevention
Chronic reflux
Esophageal adenocarcinoma

ASJC Scopus subject areas

Gastroenterology

Access to Document

10.1016/j.gtc.2015.02.009

Cite this

@article{e26b63104eb64473a59919261d3b2488,

title = "Chemoprevention in Barrett's Esophagus: Current Status",

abstract = "Chemoprevention in Barrett's esophagus is currently applied only in research settings. Identifying pathways that can be targeted by safe, pharmaceutical or natural compounds is key to expanding the scope of chemoprevention. Defining meaningful surrogate markers of cancer progression is critical to test the efficacy of chemopreventive approaches. Combinatorial chemoprevention that targets multiple components of the same pathway or parallel pathways could reduce the risk and improve the efficacy of chemoprevention. Here we discuss the role of chemoprevention as an independent or an adjuvant management option in BE-associated esophageal adenocarcinoma.",

keywords = "Barrett's esophagus, Chemoprevention, Chronic reflux, Esophageal adenocarcinoma",

author = "Zeb, {Muhammad H.} and Anushka Baruah and Kossak, {Sarah K.} and Buttar, {Navtej S.}",

note = "Publisher Copyright: {\textcopyright} 2015 Elsevier Inc.",

year = "2015",

month = jun,

day = "1",

doi = "10.1016/j.gtc.2015.02.009",

language = "English (US)",

volume = "44",

pages = "391--413",

journal = "Gastroenterology Clinics of North America",

issn = "0889-8553",

publisher = "W.B. Saunders Ltd",

number = "2",

}

TY - JOUR

T1 - Chemoprevention in Barrett's Esophagus

T2 - Current Status

AU - Zeb, Muhammad H.

AU - Baruah, Anushka

AU - Kossak, Sarah K.

AU - Buttar, Navtej S.

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Chemoprevention in Barrett's esophagus is currently applied only in research settings. Identifying pathways that can be targeted by safe, pharmaceutical or natural compounds is key to expanding the scope of chemoprevention. Defining meaningful surrogate markers of cancer progression is critical to test the efficacy of chemopreventive approaches. Combinatorial chemoprevention that targets multiple components of the same pathway or parallel pathways could reduce the risk and improve the efficacy of chemoprevention. Here we discuss the role of chemoprevention as an independent or an adjuvant management option in BE-associated esophageal adenocarcinoma.

AB - Chemoprevention in Barrett's esophagus is currently applied only in research settings. Identifying pathways that can be targeted by safe, pharmaceutical or natural compounds is key to expanding the scope of chemoprevention. Defining meaningful surrogate markers of cancer progression is critical to test the efficacy of chemopreventive approaches. Combinatorial chemoprevention that targets multiple components of the same pathway or parallel pathways could reduce the risk and improve the efficacy of chemoprevention. Here we discuss the role of chemoprevention as an independent or an adjuvant management option in BE-associated esophageal adenocarcinoma.

KW - Barrett's esophagus

KW - Chemoprevention

KW - Chronic reflux

KW - Esophageal adenocarcinoma

UR - http://www.scopus.com/inward/record.url?scp=84929879338&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929879338&partnerID=8YFLogxK

U2 - 10.1016/j.gtc.2015.02.009

DO - 10.1016/j.gtc.2015.02.009

M3 - Review article

C2 - 26021201

AN - SCOPUS:84929879338

SN - 0889-8553

VL - 44

SP - 391

EP - 413

JO - Gastroenterology Clinics of North America

JF - Gastroenterology Clinics of North America

IS - 2

ER -

Chemoprevention in Barrett's Esophagus: Current Status

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this